A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

Eur Neurol. 2000;44(4):236-41. doi: 10.1159/000008243.

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Age Factors
  • Aged
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / physiopathology
  • Carbamates / administration & dosage*
  • Carbamates / adverse effects
  • Cholinesterase Inhibitors / administration & dosage*
  • Cholinesterase Inhibitors / adverse effects
  • Cognition / drug effects
  • Cognition / physiology
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Phenylcarbamates*
  • Rivastigmine
  • Time Factors
  • Treatment Outcome

Substances

  • Carbamates
  • Cholinesterase Inhibitors
  • Phenylcarbamates
  • Rivastigmine